NTHU
19.2.2020 10:02:05 CET | Business Wire | Press release
A research team led by Professor Hsueh-Shih (Sean) Chen of National Tsing Hua University has recently announced that they have developed a new quantum dot material which is more stable and provides more realistic color. The main limitations of the current quantum dot display materials is that they are unstable and easily damaged, and the team has rectified this by growing “shield” with approximately 1-nanometer at the crystal facets of each quantum dot. The new material has a wide range of applications, including the screens used in televisions, computers, mobile phones, and cameras.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005017/en/
With the support of NTHU, the team has already applied for patents for the new material and has established the HsinLight Inc. to produce it on a commercial scale. It is expected that the first quantum dot screens will begin production in 2020.
Most of the displays currently on the market are liquid crystal displays (LCD), which have a color gradation and saturation and can only display about one third of the colors visible to the human eye, and even the so-called “retinal grade” OLED displays used in such devices as iPhone 11 can only display about half of the colors visible to the human eye. Displays equipped with new QD material (QLED TV) will display nearly 90% of the colors visible to the human eye.
However, there are still a few challenges to be overcome before quantum dot material goes into widespread use. Chen explained that quantum dots are spherical crystals of about three nanometers in size, and are easily damaged by water and oxygeny molecules, which diminishes their luminosity. At present, major manufacturers such as Samsung control this problem by sandwiching the quantum dots in a layer of protective film, but it’s not cost-effective and easily lose the protective function if there is a small pin hole.
Inspired by the shield used by the comic book superhero Captain America in the Avengers series, Chen hit upon the idea of giving each quantum dot its own shields about one nanometer in size, which effectively resists water and oxidation and also increases material stability and the display’s lifespan.
In the past two years several companies have begun selling televisions with quantum dot technology, but due to the fragile nature of quantum materials, they are difficult to mass produce, and the price is relatively high. However, using Chen’s unique shield technology to protect the quantum dots will significantly reduce production costs.
A typical 55-inch quantum dot screen consists of more than 100 million trillion (10 to the 20th power) quantum crystals, and Chen's research team has developed a technique for precisely controlling the size of each quantum dot, so that each quantum crystal differs in size by no more than 0.5 nanometers. Precisely controlling the size of the quantum dots and shields allows them to accurately emit blue, green, yellow, orange, red, infrared, and other colors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
